US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody...
ReasonTV China Approved This Lung Cancer Drug. The FDA Is Making Americans Wait.
Red background with packaging for a Chinese lung cancer drug
Lean: Leans right Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: NonprofitOwner: Reason Foundation
Ibtimes FDA Rejects China's Cancer Drug as 'Blow to Beijing' Framing Unleashes Fury Over American Lung Cancer Patients
The FDA rejected ivonescimab after its trial failed to show a statistically significant overall-survival benefit, despite delaying lung cancer progression in previously treated patients.
Lean: Center Fact-focusedFactuality: Mostly factualCountry: United KingdomFunding: CorporateOwner: Independent
The Epoch Times FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed
The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. (Madalina Vasiliu/The Epoch Times)
Low reliability sourceElevated riskLean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: Epoch Media Group
Medpagetoday FDA Rejects Promising Cancer Drug Developed in China
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational...
Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent





















